| First Author | Lu S | Year | 2018 |
| Journal | Biochem Biophys Res Commun | Volume | 503 |
| Issue | 3 | Pages | 1322-1329 |
| PubMed ID | 30031609 | Mgi Jnum | J:270489 |
| Mgi Id | MGI:6277794 | Doi | 10.1016/j.bbrc.2018.07.043 |
| Citation | Lu S, et al. (2018) HDAC9 promotes brain ischemic injury by provoking IkappaBalpha/NF-kappaB and MAPKs signaling pathways. Biochem Biophys Res Commun 503(3):1322-1329 |
| abstractText | Ischemic stroke is an acute cerebrovascular disease due to poor blood flow to the brain. Nevertheless, there is still no effective therapy for it and the pathology contributing to ischemic stroke is not fully understood. Histone Deacetylase 9 (HDAC9) is a class IIa chromatin-modifying enzyme. HDAC9 gene region is a leading risk locus for large artery atherosclerotic stroke. However, the mechanisms linking HDAC9 to ischemic remain elusive. In the study, we attempted to explore HDAC9-associated inflammatory response using the wild type (WT) and HDAC9-knockout (KO) mice with brain ischemic injury. The results indicated that WT mice with ischemia brain exhibited higher expression levels of HDAC9. HDAC9 depletion resulted in a decreased infarct volume and an improved neurological function in mice after ischemic reperfusion (I/R) injury. I/R injury markedly enhanced GFAP and Iba-1 expressions in cortex and HDAC9 knockout significantly reversed this up-regulation. Loss of HDAC9 inhibited the release of inducible NO-synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin 1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha), and IL-18 in cortex, hippocampus and hypothalamus of mice with I/R injury, which occurred at the transcription levels. Furthermore, the inhibitory actions of HDAC9 deficiency were associated with the down-regulation of phosphorylated-IkappaBalpha, phosphorylated-nuclear factor-kappa B (NF-kappaB), and p-mitogen-activated protein kinases (MAPKs), including phosphorylated-p38, phosphorylated-extracellular signal-regulated kinase 1/2 (ERK1/2), and phosphorylated-c-Jun N-terminal kinase (JNK). Importantly, the in vitro study indicated that HDAC9 inhibition-reduced inflammation and activation of IkappaBalpha/NF-kappaB were restored by promoting MAPKs activity in LPS-stimulated cells. Our findings suggest that HDAC9 inhibition showed neuroprotective effects on ischemic stroke by restraining inflammation, which might help develop new and effective strategies for the therapeutic interventions in ischemic stroke. |
